A practical guide to the handling and administration of talimogene laherparepvec in Europe.

Détails

Ressource 1Télécharger: 28814886_BIB_97554E7633A7.pdf (1603.99 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_97554E7633A7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Périodique
OncoTargets and therapy
Auteur⸱e⸱s
Harrington K.J., Michielin O., Malvehy J., Pezzani Grüter I., Grove L., Frauchiger A.L., Dummer R.
ISSN
1178-6930 (Print)
ISSN-L
1178-6930
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
10
Pages
3867-3880
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection. This review provides a practical overview of handling, storage, and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be transported/stored frozen at a temperature of -90°C to -70°C, and once thawed, vials must not be refrozen. Universal precautions for preparation, administration, and handling should be followed to avoid accidental exposure. Health care providers should wear personal protective equipment, and materials that come into contact with talimogene laherparepvec should be disposed of in accordance with local institutional procedures. Individuals who are immunocompromised or pregnant should not prepare or administer this agent. Talimogene laherparepvec is administered by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. Treatment should be continued for ≥6 months. As with other immunotherapies, patients may experience an increase in the size of existing lesion(s) or the appearance of new lesions (ie, progression) prior to achieving a response ("pseudo-progression"). As several health care professionals (eg, physicians [dermatologists, surgeons, oncologists, radiologists], pharmacists, nurses) are involved in different stages of the process, there is a need for good interdisciplinary collaboration when using talimogene laherparepvec. Although there are specific requirements for this agent's storage, handling, administration, and disposal, these can be effectively managed in a real-world clinical setting through the implementation of training programs and straightforward standard operating procedures.

Mots-clé
herpes simplex virus, intralesional injection, melanoma, oncolytic immunotherapy, practical considerations, talimogene laherparepvec
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/09/2017 17:06
Dernière modification de la notice
20/08/2019 15:59
Données d'usage